NR3C2 and obesity disorder: Third, the study included participants with class II/III obesity, many of whom had been treated with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and/or mineralocorticoid receptor blockers, which may have affected steroid metabolism.